Latest Dermatology News

Mayne Pharma reported a robust 5% revenue increase to $408.1 million and more than doubled its underlying EBITDA to $47 million in FY25, driven by strong Women’s Health sales and strategic acquisitions in Dermatology.

Mayne Pharma reported a 5% revenue increase to $408.1 million for FY25 but posted a net loss of $93.8 million, narrowing from the prior year. The company’s planned acquisition by Cosette Pharmaceuticals faces legal hurdles, delaying completion.

Acrux Ltd reported a 44% revenue decline and a modest increase in net loss for FY25, while expanding its US topical generics portfolio and entering the Saudi Arabian market. The company signals a strategic pivot amid intensifying competition and lower returns.

Clinuvel Pharmaceuticals has reported a robust financial year ending June 2025, marked by solid revenue growth and sustained profitability, while advancing its clinical pipeline and maintaining a strong balance sheet.

Clinuvel Pharmaceuticals reports steady financial growth with an 8% rise in revenue and 2% profit increase, while expanding its US commercial footprint and completing recruitment for a pivotal vitiligo trial.

Mayne Pharma has firmly rejected a fresh termination notice from Cosette Pharmaceuticals alleging breaches related to FDA disclosure, escalating an ongoing contractual dispute with significant legal implications.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.

Zelira Therapeutics reports promising diabetic neuropathy study results with ZLT-L-007 surpassing Lyrica, while converting $3.25 million in notes to equity to bolster HOPE® 1 clinical development.

Botanix Pharmaceuticals reports a strong commercial ramp-up for Sofdra™, with net revenue jumping from $0.7 million to $4.3 million in one quarter, supported by a $40 million capital raise and a $30 million debt facility.

Botanix Pharmaceuticals reports robust early sales and expanding prescriber engagement for Sofdra™, its FDA-approved topical gel for excessive underarm sweating, signaling promising growth ahead.

Mayne Pharma shareholders have overwhelmingly approved a scheme for Cosette Pharmaceuticals to acquire the company, setting the stage for a pivotal court hearing later this year.

Mayne Pharma Group has proposed a $7.40 per share acquisition by Cosette Pharmaceuticals, with unanimous board support and a fair and reasonable opinion from an independent expert. Shareholders will vote on the scheme on June 18, 2025.